manilatimes27 分钟
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a ...
Initiated the Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa ...